Cytomel (Liothyronine) Cost in Indiana 2026: Cash Prices, Insurance, Medicaid & Savings

What Liothyronine T3 Actually Costs in Indiana Right Now

Generic liothyronine tablets average $35 per month at Indiana retail pharmacies as of early 2026. Brand-name Cytomel from Pfizer carries a list price near $120 per month. The gap between generic and brand is large enough that most patients, and most prescribers, default to generic unless a specific formulation concern exists.

These figures reflect a 30-day supply at standard dosing (typically 25 mcg daily, though some patients take 5 to 50 mcg split across one or two daily doses). Pricing varies by pharmacy. A CVS in Indianapolis may charge differently than an independent pharmacy in Fort Wayne or Evansville. Discount tools like GoodRx or RxSaver frequently drop the generic price below $20 at select chains [1]. The FDA-approved labeling for Cytomel confirms available tablet strengths of 5 mcg, 25 mcg, and 50 mcg, and dosing adjustments affect monthly cost directly. A patient on 50 mcg daily using two 25-mcg tablets will pay roughly double the single-tablet price unless the pharmacy carries 50-mcg tablets.

Compounded liothyronine from licensed 503A pharmacies in Indiana runs approximately $40 per month. This option appeals to patients who need custom dosing (e.g., 7.5 mcg or slow-release formulations) not available in commercial tablets. The cost difference between compounded and generic commercial product is minimal.

Why the Price Spread Is So Wide

The $35-to-$120 range between generic and brand reflects patent expiry dynamics, not clinical superiority. Cytomel (liothyronine sodium) received FDA approval decades ago, and multiple generic manufacturers now produce it. According to the FDA Orange Book, several ANDA-approved generics exist with confirmed therapeutic equivalence (AB-rated) to Cytomel.

Pfizer maintains the brand at a higher price point partly because a small subset of endocrinologists and patients prefer it for perceived consistency in tablet potency. Liothyronine is a narrow therapeutic index drug. The American Thyroid Association (ATA) 2014 guidelines noted that while generic substitution is acceptable for levothyroxine, patients on any thyroid hormone should have TSH rechecked 6 to 8 weeks after switching formulations [2]. That recommendation sometimes discourages switching but does not constitute a clinical mandate to stay on brand.

Wholesale acquisition cost (WAC) for Pfizer's Cytomel has increased at a rate exceeding general pharmaceutical inflation over the past five years, a pattern documented across many legacy endocrine drugs. Indiana pharmacies pass this through to cash-pay patients at varying margins.

Indiana Medicaid Does Not Cover Cytomel for Hypothyroidism

Indiana's Medicaid program, administered through managed care entities like Anthem, CareSource, MDwise, and MHS, does not include Cytomel or generic liothyronine on its preferred drug list for hypothyroidism treatment. Coverage is restricted to type 2 diabetes indications only. This means a Medicaid enrollee prescribed liothyronine for hypothyroidism or as adjunctive T3 therapy will face a coverage denial at the pharmacy counter.

The exclusion traces back to formulary committees prioritizing levothyroxine (T4) monotherapy as the standard of care for hypothyroidism, consistent with the ATA's 2014 guidelines, which recommend levothyroxine as first-line treatment [2]. Liothyronine combination therapy (T4+T3) remains a topic of active clinical debate. The landmark Bunevicius et al. trial (1999, NEJM) found that partial substitution of T3 for T4 improved cognitive performance, mood, and physical symptom scores in 33 hypothyroid patients, though subsequent larger trials produced mixed results [3].

For Medicaid patients who genuinely need T3 supplementation, two paths exist. First, a prescriber can submit a prior authorization (PA) request with clinical documentation (persistent symptoms despite optimized T4, suppressed T3 levels on labs). Approval rates are low but not zero. Second, the patient can pay cash for generic liothyronine at $35 per month, which is often cheaper than fighting the PA process. Some Indiana Medicaid managed care plans have slightly different formulary rules, so verifying with the specific MCO is worth the phone call.

Insurance Coverage Beyond Medicaid

Commercial insurance plans in Indiana vary widely on liothyronine coverage. Most employer-sponsored plans and ACA marketplace plans (available through the federal exchange for Indiana residents) place generic liothyronine on Tier 2 (preferred generic) or Tier 3 (non-preferred generic). Brand Cytomel typically lands on Tier 3 or Tier 4, where copays range from $40 to $75 per fill.

Anthem Blue Cross Blue Shield, the largest commercial insurer in Indiana, covers generic liothyronine without prior authorization on most of its employer plans. UnitedHealthcare and Cigna plans sold in Indiana similarly cover generic liothyronine, though formulary tier placement varies by specific plan design. The Endocrine Society's clinical practice guidelines on hypothyroidism support T3 use in selected patients, which provides a basis for appeal if a plan initially denies coverage [4].

Patients with high-deductible health plans (HDHPs) will pay full cash price until their deductible is met. For these patients, using a pharmacy discount coupon at the point of sale can be cheaper than running the claim through insurance, because the negotiated cash price ($20 to $35) may be lower than the plan's contracted rate.

Compounded Liothyronine T3 in Indiana: Legal and Available

Compounded liothyronine from 503A pharmacies is legal in Indiana. A 503A pharmacy operates under a patient-specific prescription from a licensed prescriber, compounding the medication on-site or at a licensed facility per FDA Section 503A of the FD&C Act. Indiana's Board of Pharmacy regulates these facilities under state compounding rules that align with federal 503A requirements.

The typical cost is around $40 per month for compounded liothyronine, which is only slightly higher than the generic commercial tablet. The value of compounding lies not in price but in customization. Options include sustained-release capsules designed to blunt the T3 peak that some patients experience with immediate-release tablets. A 2018 study in Thyroid found that slow-release T3 preparations produced more stable serum T3 levels compared to conventional tablets, though the clinical significance of this pharmacokinetic difference remains debated [5].

Indiana patients can access compounded liothyronine through local compounding pharmacies in cities like Indianapolis, Fort Wayne, Bloomington, and South Bend, or through mail-order 503A pharmacies licensed in Indiana. Telehealth prescribers can write prescriptions for compounded T3 that ship directly to the patient.

Telehealth Prescribing: How It Works in Indiana

Indiana permits telehealth prescribing of liothyronine without geographic restriction within the state. A prescriber licensed in Indiana (or holding an appropriate interstate license) can evaluate a patient via synchronous video or audio visit, order thyroid labs, and prescribe liothyronine electronically to any Indiana pharmacy.

The Indiana Medical Licensing Board formalized expanded telehealth rules during the COVID-19 pandemic, and the state legislature codified permanent telehealth parity provisions. For thyroid hormone prescribing specifically, there is no requirement for an in-person visit before initiating or continuing liothyronine therapy via telehealth. The prescriber must establish a legitimate provider-patient relationship, which a real-time video consultation satisfies under Indiana law.

Telehealth platforms that specialize in thyroid care or hormone optimization can often negotiate lower medication pricing through partner pharmacies, sometimes offering generic liothyronine at $15 to $25 per month as part of a membership or subscription model. This can make the total cost (consultation fee plus medication) competitive with a traditional office visit plus retail pharmacy fill, especially for patients without insurance or with high-deductible plans. The ATA recommends monitoring TSH and free T3 levels every 6 to 8 weeks after initiating or adjusting T3 therapy [2], and telehealth visits are well-suited to these follow-up lab reviews.

How to Get the Lowest Price on Liothyronine in Indiana

The cheapest route for most Indiana patients is generic liothyronine with a pharmacy discount coupon. Prices below $15 for a 30-day supply have been documented at Walmart, Kroger, and Costco pharmacies across the state when using GoodRx or similar aggregators [1].

A step-by-step approach to minimizing cost:

Step 1: Ask for generic. Unless your prescriber has a specific clinical reason, generic liothyronine (AB-rated to Cytomel) is the default. Indiana pharmacies are required to offer generic substitution unless the prescriber writes "dispense as written" (DAW).

Step 2: Compare pharmacy prices. Prices vary by $10 to $30 across pharmacies in the same city. Use a price comparison tool before filling. Independent pharmacies sometimes beat chain pricing on generic thyroid drugs.

Step 3: Apply a discount coupon. Even with insurance, running a manufacturer or third-party coupon can be cheaper than your copay, especially on high-deductible plans. Pfizer's savings program for brand Cytomel may reduce the brand copay for commercially insured patients, though eligibility excludes government insurance (Medicaid, Medicare, Tricare) [6].

Step 4: Consider 90-day fills. Many pharmacies offer a lower per-unit cost on 90-day supplies. If your dose is stable, switching from monthly to quarterly fills can save 15% to 25%.

Step 5: Evaluate compounding only if needed. If you require a custom dose or sustained-release formulation, a 503A compounding pharmacy is the right choice at approximately $40 per month. Do not pay the compounding premium for a standard dose that is commercially available.

Brand Cytomel vs. Generic vs. Compounded: Which One in Indiana?

Generic liothyronine is the right starting point for the vast majority of patients. The AB rating from the FDA means the generic must demonstrate bioequivalence to brand Cytomel within a 90% confidence interval of 80% to 125% for AUC and Cmax [7]. For a drug taken daily with regular lab monitoring, this standard is clinically sufficient.

Brand Cytomel at $120 per month is justifiable only if a patient has documented adverse reactions to generic excipients or demonstrates unexplained TSH/T3 variability on generic formulations that resolves on brand. This is uncommon. A 2004 analysis in JAMA of thyroid hormone potency found that most commercial liothyronine tablets fell within 90% to 110% of labeled potency, regardless of manufacturer [8].

Compounded T3 at $40 per month fills a real niche for patients needing doses between standard tablet strengths (e.g., 7.5 mcg, 10 mcg, or 12.5 mcg) or those whose clinicians prefer a sustained-release preparation. The tradeoff: compounded products lack the FDA-verified potency testing that commercial generics undergo. The National Academies of Sciences, Engineering, and Medicine (NASEM) 2020 report on drug compounding noted variability in potency across compounding pharmacies and recommended that patients use pharmacies accredited by the Pharmacy Compounding Accreditation Board (PCAB) [9].

Clinical Context: When T3 Therapy Is Prescribed

Liothyronine is not a first-line hypothyroidism drug. The ATA 2014 guidelines recommend levothyroxine monotherapy as the standard treatment, with combination T4+T3 therapy considered on a trial basis for patients with persistent symptoms despite biochemically adequate T4 replacement [2].

The Bunevicius et al. 1999 trial in the New England Journal of Medicine randomized 33 patients with hypothyroidism to either their usual levothyroxine dose or the same dose with 12.5 mcg of T4 replaced by 12.5 mcg of liothyronine. The T4+T3 group showed statistically significant improvements in mood, psychometric test performance, and composite neuropsychological scores [3]. The trial was small but influential. It generated the hypothesis that some patients convert T4 to T3 less efficiently and benefit from direct T3 supplementation.

Subsequent trials have been mixed. A 2006 meta-analysis in the Journal of Clinical Endocrinology & Metabolism pooling 11 randomized trials found no consistent advantage of combination therapy over T4 alone for quality of life, mood, or cognitive outcomes at the group level [10]. The debate centers on whether a subgroup of patients (possibly those with the DIO2 Thr92Ala polymorphism) preferentially benefits. A 2009 study in the Journal of Clinical Endocrinology & Metabolism reported that patients carrying this polymorphism showed greater improvement on combination therapy, though replication studies are ongoing [11].

For Indiana patients, this clinical context matters for cost planning. If your prescriber recommends a T3 trial, expect 6 to 12 weeks of dose titration with lab monitoring before reaching a stable regimen. Budget for two to three months of medication and at least two sets of thyroid labs (TSH, free T4, free T3) during the titration window.

"Based on the totality of current evidence, levothyroxine monotherapy remains the standard of care for hypothyroidism, but a trial of combination LT4/LT3 therapy is not unreasonable for patients with persistent symptoms despite adequate TSH normalization." This statement from the 2014 ATA Guidelines represents the current clinical consensus [2].

"Partial substitution of liothyronine for levothyroxine resulted in improved well-being and cognitive performance." This finding from Bunevicius et al. (1999) remains the most-cited evidence supporting T3 combination therapy [3].

Pfizer and Generic Manufacturer Savings Programs

Pfizer offers a savings card for brand Cytomel that can reduce the copay for commercially insured patients. The card typically caps the patient's out-of-pocket at $25 to $35 per fill, which makes brand Cytomel roughly equivalent in cost to generic at retail. Eligibility requires commercial insurance (not Medicare, Medicaid, or other government programs) and is subject to annual caps, usually $1,200 to $1,800 per year [6].

For uninsured patients, Pfizer's patient assistance program (Pfizer RxPathways) may provide Cytomel at no cost, though income eligibility thresholds apply (generally at or below 400% of the federal poverty level). Application requires prescriber involvement and proof of income.

Generic manufacturers do not typically offer direct savings cards, but the already-low price of generic liothyronine ($15 to $35) makes this less relevant. The better strategy for generic users is to compare prices across pharmacies and use a third-party discount platform.